Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 199 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resectable Pancreatic Carcinoma Clear all
Recruiting Phase 2 Interventional

Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

NCT05518903
View directory record Official record
Conditions
Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 2, 2026, 5:50 AM EDT
Terminated Early Phase 1 Interventional

Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas

NCT01276613
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Losartan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 2, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

NCT03410030
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreas Metastases
Interventions
High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2, Gemcitabine 1000mg/m^2, High Dose Ascorbic Acid 37.5 g/m^2, High Dose Ascorbic Acid 56.25 g/m^2, High Dose Ascorbic Acid 75 g/m^2
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 2, 2026, 5:50 AM EDT
Terminated Not applicable Interventional

Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer

NCT01760694
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Multi-Modality; IORT, Surgery, Radiation, Chemotherapy
Other
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 2, 2026, 5:50 AM EDT
Withdrawn Phase 2 Interventional

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

NCT00728000
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, Oxaliplatin, Erlotinib
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 2, 2026, 5:50 AM EDT
Withdrawn No phase listed Observational

Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer

NCT05379907
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
SIGNATERA™ ctDNA testing
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 2, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02427841
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions
Fluorouracil, Gemcitabine, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Nab-paclitaxel, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 2, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT04858334
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
452
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 305 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
Interventions
FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 2, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

ctDNA Assay in Patients With Resectable Pancreatic Cancer

NCT05052671
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 2, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

NCT00557492
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
Drug · Radiation
Lead sponsor
Amer Zureikat
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 2, 2026, 5:50 AM EDT
Not listed Not applicable Interventional

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas

NCT00079365
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, brachytherapy, phosphorus P32, radiation therapy
Drug · Radiation
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 2, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02562716
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions
Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Oxaliplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pancreatectomy
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
807
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 515 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 2, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

NCT06423326
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nab-paclitaxel, Pancreatic Surgical Procedure
Procedure · Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 2, 2026, 5:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

NCT04327986
View directory record Official record
Conditions
Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions
M7824, M9241, SBRT
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 2, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy

NCT06595160
View directory record Official record
Conditions
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 2, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

NCT02405585
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Interventions
mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT, Gemcitabine
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 2, 2026, 5:50 AM EDT
Not listed Phase 1 Interventional

Intraoperative Radiation Therapy for Resectable Pancreas Cancer

NCT02599662
View directory record Official record
Conditions
Pancreas Cancer
Interventions
10 Gy Low-KV IORT, 15 Gy Low-KV IORT, 20 GY Low-KV IORT
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 2, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional

CREO - Microwave Ablation Feasibility Study

NCT07817147
View directory record Official record
Conditions
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic), Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Liver Cancer Stage IV, Liver Cancer Stage IIIa, Liver Cancer Stage IIIb, Liver Cancer Stage IIIc
Interventions
EUS-Guided MWA Device
Device
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Gilbert, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 5:50 AM EDT
Recruiting Phase 1 Interventional

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT06141031
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
TTI-101, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 5:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

NCT01431794
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
LDE225-600mg, Gemcitabine, nab-paclitaxel, LDE225-400mg, LDE225-800mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 2, 2026, 5:50 AM EDT
Terminated Phase 2 Interventional Results available

Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer

NCT03344172
View directory record Official record
Conditions
Pancreatic Cancer Resectable
Interventions
Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab, Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
Drug
Lead sponsor
Nathan Bahary, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 2, 2026, 5:50 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Project Survival-Prospective Biomarker Discovery

NCT02781012
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer, Pancreatitis, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
436 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
6
States / cities
Gilbert, Arizona • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 2, 2026, 5:50 AM EDT
Recruiting Phase 2 Interventional

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

NCT02598349
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton Radiation, Capecitabine, Surgical resection
Radiation · Drug · Procedure
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2040
U.S. locations
4
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 5:50 AM EDT